Valuation: Alpha Cognition Inc.

Market Cap 248M 176M 158M 144M 132M 16.56B 256M 1.74B 694M 8.84B 661M 647M 27.89B P/E 2026 *
-6.15x
P/E 2027 * -11.5x
Enterprise Value 248M 176M 158M 144M 132M 16.56B 256M 1.74B 694M 8.84B 661M 647M 27.89B EV / Sales 2026 *
6.92x
EV / Sales 2027 * 3.73x
Free-Float
94.87%
Yield 2026 *
-
Yield 2027 * -
1 day+2.82%
1 week-4.12%
Current month-4.12%
1 month-6.68%
3 months-3.34%
6 months+31.35%
Current year+28.92%
1 week 8
Extreme 8
8.95
1 month 7.98
Extreme 7.9768
9.36
Current year 4.5
Extreme 4.5
10.14
1 year 4.5
Extreme 4.5
10.14
3 years 3.75
Extreme 3.75
18.5
5 years 3.5
Extreme 3.5025
27
10 years 3.5
Extreme 3.5025
45
Manager TitleAgeSince
Chief Executive Officer 58 12/04/2021
Chief Tech/Sci/R&D Officer - 22/03/2021
Director of Finance/CFO 48 21/10/2024
Director TitleAgeSince
Director/Board Member 41 18/03/2021
Director/Board Member 66 22/03/2021
Director/Board Member 58 12/04/2021
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26
Opaleye Management, Inc.
BuyCompany 19,050 0.0875%
25/09/26
Opaleye Management, Inc.
BuyCompany 13,426 0.0616%
16/09/26
Opaleye Management, Inc.
BuyCompany 80,170 0.3681%
Change 5-day change 1-year change 3-year change Capi.($)
+2.82%-4.12%+47.02%+28.92% 177M
+0.84%-4.00%+45.17%+128.64% 1,216B
+1.35%+0.62%+47.03%+81.21% 656B
-1.04%-1.45%+32.67%+105.81% 509B
-0.36%-3.25%+47.17%+64.58% 384B
-0.46%-1.93%+70.95%+40.54% 362B
-0.78%-0.52%+30.57%+57.98% 311B
-0.80%-0.21%+8.54%+35.56% 293B
-0.03%-0.97%+46.23%+69.15% 249B
-0.44%-1.93%+35.65%+106.30% 208B
Average -0.07%-0.59%+41.10%+71.87% 418.8B
Weighted average by Cap. -0.43%+0.03%+42.29%+88.53%

Financials

2026 *2027 *
Net sales 35.87M 25.44M 22.82M 20.86M 19.04M 2.39B 37M 251M 100M 1.28B 95.51M 93.46M 4.03B 66.62M 47.26M 42.38M 38.73M 35.36M 4.44B 68.72M 467M 186M 2.37B 177M 174M 7.48B
Net income -40.64M -28.83M -25.86M -23.63M -21.57M -2.71B -41.92M -285M -114M -1.45B -108M -106M -4.56B -20.19M -14.32M -12.84M -11.74M -10.72M -1.35B -20.83M -141M -56.42M -718M -53.75M -52.6M -2.27B
Net Debt - -
Projected Income Statement - Annual - Alpha Cognition Inc.
Logo Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
Employees
-
Date Price Change Volume
07/11/26 $8.380 +2.82% 96,293
05/11/26 $8.150 -4.45% 60,186
04/11/26 $8.530 +4.02% 169,037
03/11/26 $8.200 -1.68% 108,033
02/11/26 $8.340 -4.58% 57,339
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Alpha Cognition Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
8.150USD
Average target price
18.00USD
Spread / Average Target
+120.86%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alpha Cognition Inc.
  1. Stock Market
  2. Stocks
  3. ACOG Stock